FORMULATIONS OF L-ORNITHINE PHENYLACETATE
Some embodiments of the present application are directed to oral formulations of L-ornithine phenylacetate and methods of preparing the same. These oral formulations offer alternative administration route than the standard intravenous administration of L-ornithine phenylacetate for treating hyperammonemia in patients having various acute and chronic liver diseases and disorders, for example, acute liver failure, liver cirrhosis, liver decompensation, portal hypertension, hepatic encephalopathy, or patients with urea cycle disorders.
1 . An oral pharmaceutical formulation, comprising L-ornithine phenylacetate at an oral dosage of about 2.0 g to about 10.0 g, and one or more pharmaceutically acceptable excipients or carriers.
2 . The oral pharmaceutical formulation of claim 1 , wherein the formulation provides an immediate release profile of L-ornithine phenylacetate upon oral administration.
3 . (canceled)
4 . The oral pharmaceutical formulation of claim 1 , wherein the oral dosage is about 5.0 g to about 7.5 g.
5 . (canceled)
6 . (canceled)
7 . The oral pharmaceutical formulation of claim 1 , wherein the formulation is in two or more unit dosage forms.
8 . (canceled)
9 . The oral pharmaceutical formulation of claim 1 , wherein the formulation provides conversion of phenylacetate to phenylacetylglutamine over 24 hours of greater than about 30%.
10 . (canceled)
11 . (canceled)
12 . An oral pharmaceutical formulation, comprising an effective amount of L-ornithine phenylacetate, and one or more pharmaceutically acceptable excipients or carriers, wherein upon oral administration, the formulation has a controlled release profile of L-ornithine and phenylacetate.
13 . The oral pharmaceutical formulation of claim 12 , comprising a core and one or more controlled release coating layers on the core, wherein the core comprises L-ornithine phenylacetate and said controlled release coating layers comprise one or more polymers.
14 . The oral pharmaceutical formulation of claim 13 , wherein the polymer is selected from alkyl cellulose, hydroxyalkyl cellulose, carboxyalkyl cellulose, alkylvinyl polymers, acrylic acid polymers or copolymers, acrylate polymers or copolymers, or natural or synthetic gums.
15 . (canceled)
16 . (canceled)
17 . (canceled)
18 . The oral pharmaceutical formulation of claim 13 , comprising two or more coating layers.
19 . The oral pharmaceutical formulation of claim 12 , wherein the formulation is in the form of a tablet, a capsule, a pill, pellets or free-flowing powder.
20 . (canceled)
21 . The oral pharmaceutical formulation of claim 12 , comprising about 1.0 g to about 20.0 g L-ornithine phenylacetate.
22 . (canceled)
23 . (canceled)
24 . The oral pharmaceutical formulation of claim 12 , comprising about 5.0 g to about 8.0 g L-ornithine phenylacetate.
25 . The oral pharmaceutical formulation of claim 12 , wherein said L-ornithine phenylacetate has an in vitro dissolution profile in a dissolution test of USP Apparatus 2 Paddle Method of between about 5% and 30% of L-ornithine phenylacetate released in 2 hours.
26 . The oral pharmaceutical formulation of claim 25 , wherein said L-ornithine phenylacetate has an in vitro dissolution profile in a dissolution test of USP Apparatus 2 Paddle Method of between about 15% and 80% of L-ornithine phenylacetate released in 4 hours.
27 . The oral pharmaceutical formulation of claim 26 , wherein said L-ornithine phenylacetate has an in vitro dissolution profile in a dissolution test of USP Apparatus 2 Paddle Method of between about 50% and 95% of L-ornithine phenylacetate released in 6 hours.
28 . A method for treating hyperammonemia, comprising orally administering to a subject in need thereof a pharmaceutical formulation comprising L-ornithine phenylacetate.
29 . The method of claim 28 , wherein the subject has acute liver failure or chronic liver disease.
30 . The method of claim 29 , wherein the subject has liver cirrhosis or liver decompensation.
31 . The method of claim 28 , wherein the subject has hepatic encephalopathy, portal hypertension, or a urea cycle disorder.
32 . (canceled)
33 . (canceled)
34 . (canceled)
35 . (canceled)
36 . The method of claim 28 , wherein L-ornithine phenylacetate is administered in a dose ranging from about 100 mg/kg to about 250 mg/kg.
37 . (canceled)
38 . (canceled)
39 . The method of claim 28 , wherein L-ornithine phenylacetate is administered in an amount from about 5.0 g to about 30.0 g per day.
40 . (canceled)
41 . The method of claim 28 , wherein said pharmaceutical formulation is administered at least once a day.
42 . (canceled)
43 . The method of claim 28 , wherein L-ornithine phenylacetate is administered in a dose ranging from about 2.0 g to about 10.0 g.
44 . The method of claim 43 , wherein the dose is administered in two or more unit dosage forms.
45 . The method of claim 43 , wherein the dose is administered three times a day.
46 . The method of claim 28 , wherein the plasma Cmax of L-ornithine is from about 18 mg/L to about 35 mg/L.
47 . (canceled)
48 . The method of claim 28 , wherein the plasma Cmax of phenylacetic acid is from about 50 mg/L to about 90 mg/L.
49 . (canceled)
50 . The method of claim 28 , wherein the plasma Cmax of phenylacetylglutamine is from about 30 mg/L to about 45 mg/L.
51 . The method of claim 28 , wherein said pharmaceutical formulation provides conversion of phenylacetate to phenylacetylglutamine over 24 hours of greater than about 30%.
52 . (canceled)
53 . (canceled)
54 . The method of claim 28 , comprising orally administering 3 to 6 unit dosage forms each comprising from about 0.75 g to about 2.0 g of L-ornithine phenylacetate.
55 . (canceled)
56 . The method of claim 54 , wherein said administration is repeated 3 times per day.
57 . (canceled)